GF Fund Management CO. LTD. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 292,840 shares of the biopharmaceutical company's stock after buying an additional 8,484 shares during the period. Gilead Sciences comprises about 0.8% of GF Fund Management CO. LTD.'s holdings, making the stock its 29th largest position. GF Fund Management CO. LTD.'s holdings in Gilead Sciences were worth $32,813,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of the stock. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at $25,000. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter worth about $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares in the last quarter. Investment Research & Advisory Group Inc. lifted its holdings in Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares in the last quarter. Finally, Synergy Investment Management LLC purchased a new stake in Gilead Sciences during the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have weighed in on GILD shares. Oppenheimer decreased their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Morgan Stanley increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.
View Our Latest Stock Report on GILD
Gilead Sciences Trading Down 0.3%
Shares of NASDAQ:GILD traded down $0.38 during trading on Monday, hitting $111.37. The company had a trading volume of 1,512,621 shares, compared to its average volume of 7,681,889. The stock has a market cap of $138.53 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a one year low of $66.34 and a one year high of $119.96. The company has a fifty day simple moving average of $107.02 and a two-hundred day simple moving average of $104.11. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.
Insider Buying and Selling
In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider owned 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the sale, the chief financial officer directly owned 165,110 shares in the company, valued at $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,500 shares of company stock valued at $6,340,745 over the last quarter. 0.27% of the stock is owned by corporate insiders.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
